UK markets closed

Addex Therapeutics Ltd (0QNV.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
0.1859-0.0711 (-27.67%)
At close: 06:12PM BST
Full screen
Previous close0.2570
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume7,344,000
Avg. volume140,000
Market cap51,634
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.5260
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Addex to Present at the Swiss Biotech Day 2024

    Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland. In his live presentation, scheduled for 13:45 – 14:00 CEST, on April 23, 2024, in the Samarkand room on the third floor, Mr. Dyer will provide a corporat

  • Globe Newswire

    Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

    Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 18, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation

  • Globe Newswire

    Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

    Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:0